ASPIRE PHARMA LIMITED
Get an alert when ASPIRE PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£8.5M
-12.1% lowest in 6 filed years
Net assets
£66M
+35.6% highest in 6 filed years
Employees
100
+26.6% highest in 6 filed years
Profit before tax
£25M
+22.7% highest in 6 filed years
Net assets
6-year trend · vs Consumer Discretionary median
Accounts
6-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|---|
| Turnover | £58,928,938 | £55,560,110 | £62,703,489 | — | £99,113,709 | £114,959,408 | +16% | |
| Operating profit | £18,554,587 | £19,010,364 | £13,323,640 | — | £20,220,553 | £24,692,400 | +22.1% | |
| Profit before tax | £18,899,897 | £19,010,490 | £13,345,542 | £20,557,617 | £20,320,873 | £24,929,242 | +22.7% | |
| Net profit | £15,573,573 | £15,482,125 | £11,225,364 | £19,837,187 | £19,533,952 | £23,092,481 | +18.2% | |
| Cash | £10,764,692 | £9,669,511 | £9,189,523 | £8,838,159 | £9,678,345 | £8,506,998 | -12.1% | |
| Total assets less current liabilities | £30,478,613 | £38,926,191 | £46,443,248 | £48,216,951 | £49,527,694 | £66,901,315 | +35.1% | |
| Net assets | £29,014,412 | £38,687,260 | £46,229,764 | £48,216,951 | £48,507,716 | £65,800,197 | +35.6% | |
| Equity | £29,014,412 | £38,687,260 | £46,229,764 | £48,216,951 | £48,507,716 | £65,800,197 | +35.6% | |
| Average employees | 51 | 58 | 63 | 71 | 79 | 100 | +26.6% | |
| Wages | £2,743,808 | £2,782,916 | £8,257,603 | £3,326,642 | £4,016,595 | £6,299,195 | +56.8% | |
| Directors' remuneration | £136,534 | £226,782 | £1,717,784 | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Operating margin | 31.5% | 34.2% | 21.2% | — | 20.4% | 21.5% | |
| Net margin | 26.4% | 27.9% | 17.9% | — | 19.7% | 20.1% | |
| Return on capital employed | 60.9% | 48.8% | 28.7% | — | 40.8% | 36.9% | |
| Gearing (liabilities / total assets) | — | — | — | — | 37.2% | 31.7% | |
| Current ratio | — | — | — | — | 2.28x | 2.45x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- TC Group
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- ASPIRE PHARMA LIMITED · parent
- Dermato Logical Limited 100%
- Cenote Pharma Limited 100%
- Aspire Pharma GmbH 100%
- APIE Limited 100%
Significant events
- “Aspire made two strategic acquisitions in 2024 in acquiring Cenote Pharma Ltd & the assets of Canute Pharma Ltd, both bringing complementary products to the Aspire portfolio that align to our strategy in providing cost effective niche medicines to patients, healthcare professionals and providers.”
- “In 2024 Aspire launch 10+ new products on the back of licences approvals.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BUCKLEY, Gary David | Secretary | 2020-06-15 | — | — |
| BUCKLEY, Gary David | Director | 2020-06-15 | Feb 1986 | British |
| CONDON, Richard Michael | Director | 2023-04-28 | Aug 1976 | British |
| MAY, Jonathan Charles | Director | 2020-06-15 | Apr 1970 | British |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ROBERTS, Debra Joy | Secretary | 2013-11-12 | 2020-05-31 |
| DAMANAKIS, Emmanouil | Director | 2010-11-15 | 2014-12-09 |
| DOUGLAS, James | Director | 2009-02-24 | 2009-05-14 |
| FRASER-PYE, Graham Julian | Director | 2009-06-22 | 2021-09-03 |
| GREEN, Julie Anne | Director | 2009-06-22 | 2013-11-21 |
| HILL, Jane | Director | 2009-05-14 | 2011-02-28 |
| JACOBSON, Ian | Director | 2014-12-09 | 2021-09-03 |
| KADIS, Dimitris | Director | 2010-01-11 | 2010-10-11 |
| KAHAN, Barbara | Director | 2009-02-24 | 2009-02-24 |
| PODOLSKY, Craig | Director | 2020-06-15 | 2021-09-03 |
| ROBERTS, Debra Joy | Director | 2013-11-12 | 2020-05-31 |
| ROBERTS, Mark Derek | Director | 2014-12-09 | 2021-09-03 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Aphl 2 Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-19 | Active |
| Aphl 1 Limited | Corporate entity | Shares 75–100%, Voting 75–100% (as trust) | 2019-09-04 | Ceased 2019-09-19 |
| Aspire Pharma Holdings Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2019-09-04 |
Filing timeline
Last 20 of 102 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-01-10 MA Memorandum articles
- 2024-01-10 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-04 | AA | accounts | Accounts with accounts type full | |
| 2024-08-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-07-25 | AA | accounts | Accounts with accounts type full | |
| 2024-01-10 | MA | incorporation | Memorandum articles | |
| 2024-01-10 | RESOLUTIONS | resolution | Resolution | |
| 2023-08-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-12 | AA | accounts | Accounts with accounts type full | |
| 2023-05-02 | CH01 | officers | Change person director company with change date | |
| 2023-05-02 | CH01 | officers | Change person director company with change date | |
| 2023-05-02 | AP01 | officers | Appoint person director company with name date | |
| 2022-09-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-07-08 | AA | accounts | Accounts with accounts type full | |
| 2021-12-08 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2021-09-14 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-14 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-14 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-14 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-09-03 | MR04 | mortgage | Mortgage satisfy charge full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.